Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-03-20
2007-03-20
Le, Long V. (Department: 1641)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007100, C435S007920, C435S007940, C436S514000, C436S533000, C436S534000
Reexamination Certificate
active
10002842
ABSTRACT:
A method for aiding in differentiating irritable bowel syndrome from inflammatory bowel disease by determining the level of total endogenous human lactoferrin in clinical specimens, such as feces, mucus and bile, wherein an elevated level of lactoferrin substantially precludes diagnoses of IBS and other noninflammatory etiologies, and a kit usable in such method are provided. Further provided is a method for quantitating the level of total endogenous human lactoferrin in clinical specimens, such as feces, mucus and bile, to monitor gastrointestinal inflammation in persons having inflammatory bowel disease.
REFERENCES:
patent: 5124252 (1992-06-01), Guerrant et al.
patent: 5455160 (1995-10-01), Fagerhol et al.
patent: 5552292 (1996-09-01), Uchida et al.
patent: 6008335 (1999-12-01), Rotter et al.
Sugi et al. “Fecal lactoferrei as a marker for disease activity in infammatory bowel disease: compariosn withother neutrophil-derived proteins.” The American Journal of Gastroenterology, vol. 91, No. 5, 1996, pp. 927-934.
Pool et al. “Serum antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease . . . ” Gut, 1993, 46-50.
Peen et al. “Distribution of lactoferrin and 60/65kDa heat shock protein in normal and inflamed human intestine and liver.” Gut, 1996, 38, 135-140.
Peen et al. Anti-lactoferrein antibodies and other types pf ANCA in ulcerative colitis, primary sclerosing cholangitis, and Crohn;s disease. Gut, 1993, 34, 56-62.
Kruzel et al. (Advances in Experimental Medicine and Biology, 1998, 443, pp. 167-173- Abstract Only).
Trulove SC, Witts LJ. Cortisone in Ulcerative Colities. Final Report on a Therapeutic Trial. British Medical Journal 1955; 4947:1041-1048.
Baveye, S., Elass, E., Mazurier, J., Spik, G., Legrand, D. Lactoferrine: a Multifunctional Glycoprotein Involved in the Modulation of the Inflammatory Response. Clin. Chem. Lab Med. 1999; 37(3):281-86.
Suleiman S, Sonnenberg A. Cost-effectiveness of Endoscopy in Irritable Bowel Syndrome. Arch Intern Med 2001; 161:369-75.
Levay, PF and Viljoen, J. Lactoferrin: a General Review. Haematologica. 1995; 80(3):256-67.
Roseth AG, Aadland E. Jahnsen J. Raknerud N. Assessment of Disease Activity in Ulcerative Colitis by Faecal Calprotectin, a Novel Granulocyte Marker Protein. Digestion 1997, 58:176-80.
Lagerholm S., Dutta SK, Merchant, NB, Nair, PP. COX-2 Expression in Fecal Colonocytes from Patients with Inflammatory Bowel Disease. Gastro 2001; 120:A16.
Hammer J., Talley NJ. Diagnostic Criteria for the Irritable Bowel Syndrome. Am. J. Med. 1999; 107:5S-11S.
Limburg, P.L., Ahlquist, D.A. Sandborn, W., et al. Fecal Calprotectin Levels Predict Colorectal Inflammation among Patients with Chronic Diarrhea Referred for Colonoscopy. Amer. J. of Gastro. 2000; 95:2831-2837.
Steiner TS, Flores CA, Pizarro TT, Guerrant RL. Fecal Lactoferrin, Interleukin-1 Beta, and Interleukin-8 Are Elevated in Patients with Severe Clostridium Difficile Colitis. Clin Diagn Lab Immunol 1997; 4:719-22.
Naidu, A., Satyanarayan and Arnold R. 1997. Influence of Lactoferrin on Host-Microbe Interactions. In T. William Hutchens and Bo Lonnerdal (ed.), Lactoferrin, pp. 259-275. Humana Press.
Andus T., Gross V., Caesar I., et al. PMN-elastase in Assessment of Patients with Inflammatory Bowel Disease. Dig. Dis. Sci. 1993; 35:97-105.
Tibble JA, Sigthorsson G, Bridger S. Fagerhol MK, Bjarnason I. Surrogate Markers of Intestinal Inflammation Are Predictive of Relapse in Patients with Inflammatory Bowel Disease. Gastroenterology 2000; 119:15-22.
Dwarakanath, AD, Finnie, IA, Beesley, C M, et al. Differential Excretion of Leukocyte Granule Components in Inflammatory Bowel Disease: Implications for Pathogenesis. Clin. Sci. 1997; 92:307-313.
Riley, L.W. 1995. Acute Inflammatory Diarrhea. In M. Blaser (ed.), P. Smith, J. Ravdin, H. Greenberg, and R. Guerrant,Infections of the Gastrointestinal Tract.Raven Press, New York, NY.
Tauxe, R., and M. Cohen. 1995. Epidemiology of Diarrheal Diseases in Developed Countries. In M. Blaser, P. Smith, J. Ravdin, H. Greenberg, and R. Guerrant (ed.),Infections of the Gastrointestinal Tract.Raven Press, New York, NY.
Sartor, R.B. 1995. Microbial Agents in Pathogenesis, Differential Diagnosis, and Complications of Inflammatory Bowel Disease. In M. Blaser, P. Smith, J. Ravdin, H. Greenberg, and R. Guerrant (ed.),Infections of the Gastrointestinal Tract.Raven Press, New York, NY.
Mathias, JR, Clench, MH, Reeves-Darby, VG, et al. Effect of Leuprolide Acetate in Patients with Moderate to Severe Functional Bowel Disease: Double-Blind, Placebo-Controlled Study. Dig Dis Sci, 1994; 39(6):1155-62.
Uchida, K., R. Matsuse, S. Tomita, K. Sugi, O. Saitoh, and S. Ohshiba. 1994. Immunochemical Detection of Human Lactoferrin in Feces as a New Marker for Inflammatory Gastrointestinal Disorders and Colon Cancer. Clin. Biochem. 27:259-264.
Sugi, K., Saitoh, O., Hirata, I., and K. Katsu. 1996. Fecal Lactoferrin as a Marker for Disease Activity in Inflammatory Bowel Disease: Comparison with Other Neutophil-derived Proteins. Amer. J. Gastroenterol. 91:927-934.
Guerrant, R.L., V. Araujo, E. Soares, K. Kotloff, A. Lima, W. Cooper, and A. Lee. 1992. Measurement of Fecal Lactoferrin as a Marker of Fecal Leukocytes. J. Clin. Microbiol. 30:1238-1242.
Fine, K.D., F. Ogunji, J. George M Niehause, and R. Guerrant, 1998. Utility of a Rapid Fecal Latex Agglutination Test Detecting the Neutrophil Protein, Lactoferrin, for Diagnosing Inflammatory Causes of Chronic Diarrhea. Amer. J. Gastroenterol. 93:1300-1305.
Camilleri, M. 2001. Management of Irritable Bowel Syndrome. Gastroenterol. 120:652-668.
Calkins, Beverly M., Everhart, J.E. Ed 1994. Inflammatory Bowel Diseases, Digestive Diseases in the United States: Epidemiology and Impact., Chapter 16, pp. 509-550 U.S. Department of Health and Human Services, National Institute of Health, National Institute of Diabetes and Digestive and Kidney Disease, U.S. Government Printing Office, NIH Publication No. 94-1447.
Sandler, Robert, Everhart, J.E. 1994. Irritable Bowel Syndrome, Digestive Diseases in the United States: Epidemiology and Impact., Chapter 19, pp. 595-612, U.S. Department of Health and Human Services, National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases. U.S. Government Printing Office, NIH Publication No. 94-1447.
Harris, J.C., H.L. DuPont, and B.R. Hornick. 1971. Fecal Leukocytes in Diarrheal Illness. Ann. Intern. Med. 76:697-703.
Tibble, J., Teahon, K., Thjodleifsson, B., et al., “A Simple Method for Assessing Intestinal Inflammation in Crohn's Disease” Gut 2000;47-506-513.
Saitoh, O., Kojima, K., Sugi, K., et al., “Fecal Eosinophil Granule-Derived Proteins Reflect Disease Activity in Inflammatory Bowel Disease” AJG 1999; vol. 94 No. 12.
Tibble, J.A. and Bjarnason, I., “Non-Invasive Investigation of Inflammatory Bowel Disease” World J Gastroenterol, 2001;7(4):460-465.
Tabata K.; Matsuse R.; Uchida K.; and Amemoto K.; “Measurement of Fecal Lactoferrin for Diagnosis on Pediatric Gastrointestinal Disease” (Abstract) The Japanese Journal of Clinical Pathology, 1997;45(12):1201-1203.
Boone James Hunter
Guerrant Richard Littleton
Lyerly David Maxwell
Wilkins Tracy Dale
Cook Lisa V.
Le Long V.
Shook Hardy & Bacon LLP
Techlab, Inc.
LandOfFree
Method for differentiating irritable bowel syndrome from... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for differentiating irritable bowel syndrome from..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for differentiating irritable bowel syndrome from... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3787450